A Randomized Placebo-Controlled N-of-1 Trial: The Effect of Proton Pump Inhibitor in the Management of Gastroesophageal Reflux Disease.
Conclusion: There was no significant improvement in the patient GERD symptoms increasing the dose of oral esomeprazole during the 6 months of study. N-of-1 trials in chronic pathologies including GERD are recommended due to their potential value as systematic methods that evaluate therapies without strong scientific evidence.
PMID: 31929980 [PubMed - in process]
Source: Canadian Journal of Gastroenterology - Category: Gastroenterology Tags: Can J Gastroenterol Hepatol Source Type: research
More News: Acid Reflux | Adenocarcinoma | Alcoholism | Canada Health | Eating Disorders & Weight Management | Esomeprazole | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Gastroesophageal Reflux Disease | GERD | Heartburn | Nexium | Obesity | Proton Pump Inhibitors PPIs | Smokers | Statistics | Study